Demonstrating the clinical utility and cost-effectiveness of innovative blood-based biomarker tests can help pave the way for making timely AD diagnosis and proactive care the norm.
The post Broadening Biomarker Validation for Alzheimer’s Disease Diagnosis Globally appeared first on MedCity News.
